Gubra enables you to progress your preclinical development for metabolic diseases with more certainty than any other research partner. We offer highly specialized services within five main disease areas.
Benefit from our extensive know-how in NASH and test your compound in our validated DIO NASH mouse models.
Qualify and advance your assessment of novel compounds to treat type 2 diabetes and diabetic complications.
Tap into our vast scientific experience with diet-induced obesity (DIO) models and other commercially available models.
Gubra imaging services across indications
Get the full picture
Using quantitative 3D light sheet microscopy, you can assess drug efficacy and drug distribution in a whole new way. The results that you get are absolute and can be easily accessed in our dataviewer GubraView.
With our interactive brain browser (Gubra 3D Explorer) you can explore individual brain regions of interest, display quantitative c-Fos data and filter for regions with statistical significant response to drug treatment.
Whole-brain activation signatures of weight-lowering drugs
Our paper on whole-brain 3D activation signatures on six different weight-lowering compounds is featured on the front cover of Molecular Metabolism (Vol 47 – May 2021).